Dear Editor, Plasma cell myeloma (PCM) is the second most common hematologic neoplasm, with a worldwide aged-standardized incidence rate of 1.5/100,000 [1] . The introduction of new therapeutic modalities, including alkylating agents and autologous stem cell transplants (ASCT), has dramatically improved the prognosis of patients with PCM; unfortunately, this has been accompanied by an increase in the incidence of secondary neoplasms [1, 2] . Therapy-related ALL (t-ALL) is uncommon and far less understood than therapy-related AML. t-ALL as a secondary neoplasm in PCM patients is extremely rare, and only two cases have been reported so far [3] [4] [5] . We report two additional cases of t-ALL in PCM patients: one who was treated with alkylating agents and topoisomerase II inhibitors simultaneously and the other one who was treated with only topoisomerase II inhibitors. These two cases are first to be reported in Korea. As this was a case report, the Institutional Review Board of Asan Medical Center, Seoul, Korea, waived the requirement for informed consent.
Case 1: A 54-year-old man had been diagnosed as having PCM (IgA κ, plasmablastic type) with a normal karyotype in March 2007 ( [1] , which differed from normal karyotype at the initial diagnosis of PCM. The patient was diagnosed as having ALL, and complete remission was achieved after one cycle of induction and two cycles of consolidation chemotherapy.
Case 2: A 52-year-old woman had been diagnosed as having PCM (IgGκ, plasmablastic type) consisting of a malignant hyperdiploid clone with structural abnormalities (52,XX,+add(3) (q12),+5,-6,-8,+9,-10,+11,+15,-17,+18,+19,+20,-22,+3mar [2] /46, XY [7] ) in June 2009 (Fig. 1C) . She was treated with two cycles of PAD regimen, leading to complete remission, and underwent ASCT. After ASCT, she was given thalidomide monotherapy until August 2016. In August 2017, she was admitted with fatigue and dizziness. PB analysis showed a WBC count of 2.4 × 10 9 /L with 6% blasts; Hb, 96 g/L; and PLT, 52.0 × 10 9 /L. The BM was infiltrated with 92% blasts (Fig. 1D ) that were immunophenotyped as precursor B-ALL (CD19+, CD20+, cytoplasmic CD22+, CD10+, and negative for all myeloid and T-cell antigens). Cytogenetics revealed a normal karyotype (46,XX [20] ). There was no evidence of relapse with PCM. She was administered six cycles of hyper cyclophosphamide, vincristine, doxorubicin, and dexamethasone chemotherapy, which led to complete remission.
The relationship between t-ALL and prior cytotoxic therapy is controversial, although topoisomerase II inhibitors may also contribute to t-ALL induction [6] . Topoisomerase II inhibitors are associated with several cytogenetic abnormalities, including 11q23, inv(16), and t(9;22), whereas alkylating agents are related to the loss of chromosomes 5 and 7 in secondary ALL [3, 7] . The treatment regimens for both of our patients included both alkylating agents and topoisomerase II inhibitors; however, Cases 1 and 2 had monosomy 7 and a normal karyotype, respectively. Of note, Tang et al. [3] postulated that secondary ALL with a normal karyotype or Ph-positivity may occur regardless of prior chemotherapy, as a causal occurrence or because of inherent genetic instability. They suggested that loss of chromosomes 5, 7, and 17 may be influenced by prior treatment with alkylating agents [3] . We also hypothesized that alkylating agents might cause new lymphoid malignancies with "myeloid-type" chromosomal abnormalities such as monosomy 7 in Case 1. Additionally, various factors, including individual genetic propensity or abnormal cytogenetics, may contribute to t-ALL patient survival; this is in contrast with the poor outcome of therapy-related myeloid neoplasms [2, 5, 7, 8] . Because of the rarity of t-ALL, further studies are required to clarify the association between characteristic cytogenetic alterations and the exposure to various cytotoxic agents in PCM patients. In conclusion, our cases showed t-ALL can occur after PCM treatment including chemotherapy and ASCT. They are first to be reported in Korea.
